TickerTalks
Browse all tickers →
TickerTalks›$PYXS
PYPYXS

Pyxis Oncology, Inc.

$PYXS·$236M·Biotechnology·Healthcare
$3.23-2.7%YTD+167.8%1Y+142.9%
Mentions · last 7 days
2026-08-19: 0 posts2026-08-20: 1 posts2026-08-21: 0 posts2026-08-22: 0 posts40%
Price updated 23h ago·X counts updated 7d ago
PYPYXS
$PYXSPyxis Oncology, Inc.
$3.23-2.71%4 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $PYXS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventSelling offAI verdict · as of 2026-08-20

Falling on heavy selling — points lower unless it turns around.

Micro-cap ADC biotech with a fresh $114M raise but unusual bearish price action — the tape is discounting a bad-news leak.

Pyxis Oncology is a clinical-stage biotech developing MICVO, an antibody-drug conjugate targeting head-and-neck cancer, plus a broader ADC pipeline. The stock is up 168% year-to-date but the recent price action has turned sharply bearish on unusual volume without a public news catalyst — a pattern the X-thread traders are treating as a bad-news leak.

  • The $114M PIPE is a real capital event: 19.6M shares at $2.55 plus accompanying warrants at $3 strike — this extends cash runway to key MICVO clinical milestones but adds significant dilution against the current ~72M share count, meaning ~27% dilution on a small float.
  • The tape action is the concerning tell: the stock has traded weak on above-average volume with X posters explicitly drawing parallels to the Pliant Therapeutics Phase 3 safety-issue leak — the pattern of 'stir on the tape without a public catalyst' has historically preceded negative clinical or FDA news 24-72 hours later.
  • The fundamentals don't yet exist to anchor the trade: quarterly revenue of $0 with an EPS burn of $0.35-$0.40 per quarter — this is entirely a binary catalyst play, and the PIPE-plus-tape action combination suggests something material is arriving before the Nov 2 Q3 print.

Trajectory is breaking-down on the unusual bearish tape; a positive MICVO clinical readout or a clean explanation for the tape action reverses the setup materially — negative clinical news or a safety-related disclosure sends the stock toward the $114M PIPE floor of $2.55 or lower.

Agrees with X sentimentX's bearish framing on 'something is wrong here' with parallels to Pliant Therapeutics' Phase 3 safety leak and the observation of unusual price action without a public catalyst is exactly the honest read on the tape. Traders buying puts explicitly and asking whether the stock should be halted is a specific pattern worth respecting.

What to watch: Any public disclosure explaining the unusual price action plus Nov 2 Q3 earnings — a clean explanation reverses the setup materially; negative clinical news or safety-related disclosure sends the stock toward the $2.55 PIPE floor.

On the calendar: 2026-11-02 — Q3 2026 earnings

micro captape bearish signalactive offering

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment7 posts analyzed · as of 2026-08-18

Chatter on Pyxis Oncology is bearish and speculation-driven around an unusual price drop. Multiple voices describe a stir on the tape, ask others to call the company, and note surprise the stock is not halted for pending news. Traders explicitly draw a parallel to the Pliant Therapeutics (PLRX) Phase 3 safety-issue leak from a few years ago, with one describing buying puts. The dominant tone is 'something is wrong here, and news likely comes after the close' rather than a fundamental thesis.

Read the AI verdict + X sentiment for $PYXS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Preclinical biotech developing antibody-drug conjugates (ADCs) targeting novel antigens on solid tumors.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PYXS.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $PYXS

Neutral — Preclinical biotech developing antibody-drug conjugates (ADCs) targeting novel antigens on solid tumors; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+51.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-173%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-6.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-59.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
8.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-136%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.40$-0.35-14.3%
Q1 2026May 14, 2026$-0.37$-0.35-5.7%
Q4 2025Mar 23, 2026$-0.29$-0.35+17.1%
Q3 2025Nov 3, 2025$-0.35$-0.36+2.8%
Next earningsMon, Nov 2·consensus EPS $-0.27

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.37$-26.0M
Q4 FY25$11.0M—104%-166%$-0.29$-10.4M
Q3 FY25$0———$-0.35$-13.3M
Q2 FY25$2.8M—100%-700%$-0.30$-17.3M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$67K$67K – $67K-$1.22-$1.35 – -$1.128
FY27$4.2M$4.2M – $4.2M-$1.21-$1.34 – -$0.968
FY28$15.8M$15.8M – $15.8M-$1.20-$2.00 – -$0.538
FY29$42.8M$42.8M – $42.8M-$1.01-$1.01 – -$1.017
FY30$114.9M$114.9M – $114.9M-$0.61-$0.61 – -$0.617

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.49%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+14.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+40.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 37.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.325-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 30Jakob DupontDirector35.0K sh$107K
+ 11 other (10 awards · 1 exempt) in window

See when $PYXS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

S-3Shelf registrationAug 20S-3
3New insider — initial holdingsJul 103
AI summary

GordonMD Global Investments LP (Beverly Hills, CA) filed a Form 3 as a new 10% owner and Director of Pyxis Oncology, Inc., reporting shared beneficial ownership of 6,468,999 shares with an event date of June 30, 2026. The form reflects both 10% owner and director status for GordonMD. A new 10%+ investor achieving board representation at Pyxis Oncology is material — this indicates a significant strategic investor taking an active governance role at the clinical-stage oncology company.

8-KMaterial agreementJul 28-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
AI summary

Pyxis Oncology entered a private placement securities purchase agreement for 19,600,153 shares at $2.551/share plus accompanying common warrants for an equal number of shares at $3.289 exercise price, raising approximately $50M gross. Dilutive PIPE for this clinical-stage oncology company with warrant coverage adding further potential dilution.

8-KShareholder voteJun 158-K — Item 5.07: Shareholder vote
AI summary

Pyxis Oncology, Inc. (PYXS) reported annual meeting vote results (Item 5.07) in an 8-K filed June 15, 2026. Body unavailable — excerpt cuts off before vote tallies are disclosed.

8-K/AOfficer or director change (amended)Apr 308-K/A — Item 5.02: Officer or director change
AI summary

PYXS disclosed a personnel change (8-K Item 5.02, dated 2026-04-30). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KPress release / Reg FDMar 238-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

PYXS reported period ending 2026-03-23 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

+ 12 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestonesglobenewswire.com·17d agoFinancial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)defenseworld.net·17d agoPyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestonesglobenewswire.com·61d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $PYXS on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport